Yasho Industries Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 15 Jul 2026 | Chemicals & Petrochemicals | Market Cap: ₹5.0K Cr
Yasho Industries expects over 40% revenue growth in FY '26, driven primarily by volume increases. Yasho Industries expects over 40% revenue growth in FY '26 driven by volume growth and market share gains, especially in export markets.
From Yasho Industries Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹4,400
Market Cap
₹5.0K Cr
P/E Ratio
95.8
How does Yasho Industries Ltd rank in Chemicals & Petrochemicals?
Compare Yasho Industries Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Yasho Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹246 Cr, net profit ₹12 Cr.
Full financials →📊 Revenue & Sales Performance
- →Yasho Industries expects over 40% revenue growth in FY '26, driven primarily by volume increases.
- →Q1 FY '26 showed 14% YoY growth; volumes grew by 33%, indicating strong operational momentum.
- →Export revenue is projected to increase from 67% to about 70% of total revenue, with strong demand from Western markets.
- →Domestic market growth is slower due to local challenges and cheap imports.
- →Capacity expansion at Pakhajan (INR75 crores capex) will come into revenue from FY '27, targeted to boost output.
- →Utilization at Pakhajan expected to rise from 50% in Q1 FY '26 to around 70-80% by Q4 FY '26.
- →Company aims to optimize product mix and increase market share even in subdued pricing.
- →Long-term plans include better asset utilization, working capital reduction, and a steady growth trajectory.
📈 Profitability & Margins
- →Yasho Industries expects over 40% revenue growth in FY '26 driven by volume growth and market share gains, especially in export markets.
- →EBITDA margins are guided to be maintained between 17% to 19% in FY '26, with no immediate plans to push beyond 19% due to geopolitical uncertainty.
- →Operational leverage is expected from better capacity utilization, especially post commissioning of INR75 crore capacity expansion in Pakhajan in FY '27.
- →Debt-to-EBITDA ratio aims to improve to around 2.5x long-term, with planned capex announcements in April '26 supporting growth.
- →R&D investments (INR25 crore) targeted to improve process efficiency and enable new product chemistry are expected to drive medium to long-term profitability.
- →Efforts to optimize working capital by reducing inventory days below 150 are expected to enhance cash flow and ROCE, supporting sustainable profit growth.
🏗️ Capital Expenditure Plans
- →Planned annual capex for FY '26 is INR 100 crores:
- → - INR 75 crores for capacity expansion at the Pakhajan facility, expected to be commissioned by Jan-Feb 2026, with revenue impact starting FY '27.
- → - INR 25 crores directed towards setting up a state-of-the-art R&D facility to enhance product development and innovation, slated for completion by October 2025.
- →Capacity expansion at Pakhajan aims to increase utilization from 50%+, with revenue addition expected to be over INR 200 crores from this investment.
- →No firm capex plan yet for FY '27; potential projects are on the drawing board, with detailed plans to be shared in April 2026.
- →Focus of capex includes:
- → - Improving existing processes and operational efficiency through R&D.
- → - Developing new chemistries for the industrial segment.
- → - Enhancing market expansion and product innovation capabilities.
💰 Fundraising & Capital Structure
- →The company has ongoing capex plans amounting to INR100 crores for FY '26, including INR75 crores for capacity expansion and INR25 crores for R&D.
- →Debt-to-EBITDA ratio target is to be below 4 by March '26 and comfortably around 2.5x in the long term.
- →There was a repayment of some debt in the recent quarter; an additional INR9 crores repayment is planned starting November 2025.
- →No specific mention of new fundraising through equity or additional debt beyond managing and reducing existing debt and funding capex from internal or existing sources was made.
- →Further capex plans for FY '27 and beyond will be communicated during the April '26 investor call.
- →Overall, the focus is on debt reduction, improving working capital, and funding expansions via planned capex without explicit mention of raising new external funds currently.
📋 Order Book & Pipeline
- →The company indicated strong order visibility backing its growth outlook.
- →Despite global macroeconomic challenges, Yasho Industries delivered its highest-ever quarterly revenue in Q1 FY '26.
- →Efforts to enhance capacity utilization and customer engagement are underway to support future growth.
- →No specific numbers or exact current order book/pending orders were disclosed during the call.
- →The management remains confident of sustained demand and market share gains.
- →Expansion plans (INR 75 crores capex at Pakhajan) and new product approvals underline robust upcoming business potential.
- →Overall, the order book appears healthy with positive momentum, supporting the company's guidance of over 40% revenue growth in FY '26.
Key Metrics
Frequently Asked Questions
What were Yasho Industries Ltd Q1 FY26 results?
Yasho Industries expects over 40% revenue growth in FY '26, driven primarily by volume increases. Yasho Industries expects over 40% revenue growth in FY '26 driven by volume growth and market share gains, especially in export markets.
What is Yasho Industries Ltd share price analysis?
Yasho Industries Ltd currently shows a neutral. The stock trades at a P/E of 95.8 with a market cap of ₹5,013 Cr. Investors should review the full earnings analysis for detailed insights.
Is Yasho Industries Ltd planning capital expenditure?
Planned annual capex for FY '26 is INR 100 crores: - INR 75 crores for capacity expansion at the Pakhajan facility, expected to be commissioned by Jan-Feb 2026, with revenue impact starting FY '27.
Keep Yasho Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.